scholarly journals Developing a multimorbidity prognostic score in elderly patients with solid cancer using administrative databases from Italy

2021 ◽  
Author(s):  
Matteo Franchi ◽  
Federico Rea ◽  
Claudia Santucci ◽  
Carlo La Vecchia ◽  
Paolo Boffetta ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Prognostic Score ◽  
Administrative Databases ◽  
Solid Cancer

scholarly journals Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Sung Min Kim ◽  
Moon Jin Kim ◽  
Hyun Ae Jung ◽  
Kihyun Kim ◽  
Seok Jin Kim ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Elderly Patients ◽  
Performance Status ◽  
Solid Cancer ◽  
Newly Diagnosed ◽  
History Of ◽  
Comorbidity Index ◽  
And Performance ◽  
The Impact

Multiple myeloma occurs primarily in elderly patients. Considering the high prevalence of comorbidities, comorbidity is an important issue for the management of myeloma. However, the impact of comorbidity on clinical outcomes has not been fully investigated. We retrospectively analyzed patients with newly diagnosed myeloma. Comorbidities were assessed based on the Charlson comorbidity index (CCI) and the Freiburg comorbidity index (FCI). The CCI is a summary measure of 19 comorbid conditions. FCI is determined by performance status, renal impairment, and lung disease. This study included 127 patients with a median age of 71 years. Approximately half of the patients had additional disorders at the time of diagnosis, and diabetes mellitus was the most frequent diagnosis (18.9%). The most significant factors for prognosis among patient-related conditions were a history of solid cancer and performance status (ECOG ≥ 2). The FCI score was divided into 3 groups (0, 1, and 2-3), and the CCI score was divided into 2 groups (2-3 and ≥4). FCI was a strong prognostic tool for OS (P>0.001) and predicted clinical outcome better than CCI (P=0.059). In conclusion, FCI was more useful than CCI in predicting overall survival in elderly patients with myeloma.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

Leukemia ◽  
2018 ◽  
Vol 32 (11) ◽  
pp. 2427-2434 ◽  
Author(s):  
Paula Rodríguez-Otero ◽  
María Victoria Mateos ◽  
Joaquín Martínez-López ◽  
Nerea Martín-Calvo ◽  
Miguel-Teodoro Hernández ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Prognostic Score

scholarly journals Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

Leukemia ◽  
2019 ◽  
Vol 33 (4) ◽  
pp. 1056-1056
Author(s):  
Paula Rodríguez-Otero ◽  
María Victoria Mateos ◽  
Joaquín Martínez-López ◽  
Nerea Martín-Calvo ◽  
Miguel-Teodoro Hernández ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Prognostic Score

Predictive factors for major complications after pancreaticoduodenectomy in patients aged 80 years or older.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 199-199
Author(s):  
Naoya Takeda ◽  
Shigeaki Sawada ◽  
Isaku Yoshioka ◽  
Kazuto Shibuya ◽  
Kenichi Tazawa ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Systemic Inflammation ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Hemoglobin Level ◽  
Nutrition Status ◽  
Complication Rates ◽  
Lymphocyte Ratio ◽  
Major Complications ◽  
Conut Score

199 Background: As the population ages, elderly patients are being diagnosed with periampullary tumors, and hence, it has been suggested that surgeons should consider the indications for pancreaticoduodenectomy (PD) in elderly patients. The aim of this study is to reveal risks and benefits of PD, and is to identify prognostic inflammatory biomarkers for major complications after PD in patients aged 80 years or older. Methods: We retrospectively analyzed the cases of 161 consecutive patients who underwent PD between January 2000 and December 2015, and compared the patients aged ≥ 80 years (n = 22) with those aged < 80 years (n = 139). Postoperative results and preoperative conditions such as nutrition status using controlling nutritional status (CONUT) score, hemoglobin level and comorbidity were assessed. Correlations were evaluated between major postoperative complications (Clavien-Dindo grade III or higher) and 6 systemic inflammation–based prognostic score such as Glasgow prognostic score (GPS), modified-GPS, High sensitive-mGPS, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (PLR), and prognostic nutritional index in elderly patients. Results: There was no operative mortality. In elderly patients, preoperative hemoglobin level was lower and CONUT score was higher than in younger patients. The complication rates and the disease-specific survival did not differ significantly between the two groups. Ten patients (45%) experienced major complications in the elderly group. Among 6 systemic inflammation–based prognostic score, only PLR was revealed as predictor of major complications (p = 0.012) and optimal cutoff value was determined to be 145.3 (sensitivity = 33%, specificity = 100%, AUC = 0.842). Conclusions: PD could be performed safely in patients aged 80 years or older. The preoperative PLR was a simple and useful predictor of major complications after PD in elderly patients.

NCOG-19. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE INSTITUTIONAL SERIES OF 160 PATIENTS

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi156-vi156
Author(s):  
Alessia Pellerino ◽  
Francesco Bruno ◽  
Edoardo Pronello ◽  
Francesca Mo ◽  
Federica Franchino ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Prognostic Score ◽  
Progression Free Survival ◽  
Free Survival ◽  
Factors Affecting ◽  
Clinical Complications ◽  
Extent Of Surgery ◽  
Comorbidity Index ◽  
Prognostic Importance

Abstract INTRODUCTION Glioblastoma (GBM) prevails in elderly patients, who often suffer from other comorbidities that may affect the outcome. The aim of the study was to investigate clinical characteristics, comorbidities, and treatment-related complications that may impact the outcome of elderly patients with GBM. PATIENTS AND METHODS In this institutional retrospective study, we included GBM patients ≥ 65 years diagnosed with glioblastoma from 2015 to 2020. We retained information about comorbidities according to Charlson Comorbidity Index (CCI), Karnofsky prognostic score (KPS), MGMTp methylation, and clinical complications during treatment or follow-up. RESULTS We included 160 patients. Median age was 72 years (65-88). Median time of follow-up was 9.25 months. Median progression-free survival (mPFS) and overall survival (mOS) were 5.84 and 9.67 months. In a multivariate analysis, factors affecting survival were: KPS after surgery ≥ 70 (mPFS: HR 0.24, 0.13-0.44; mOS: HR 0.43, 0.24–0.76. 95% CI), partial vs gross total resection (mPFS: HR 2.15, 1.23–3.77; mOS: HR 2.61, 1.34–5.07. 95% CI), MGMTp methylation (mPFS: HR 0.35, 0.22–0.55; mOS: HR 0.37, 0.24–0.76. 95% CI), and complications after surgery (mPFS: HR 2.52, 1.39–4.55; mOS: HR 2.96, 1.63–5.40. 95% CI). Conversely, age and CCI were not significantly correlated with prognosis. CONCLUSIONS For elderly patients with GBM, CCI does not seem to predict the outcome. Other factors such as extent of surgery, MGMTp methylaton, postoperative KPS, and clinical complications after surgery retain a significant prognostic importance. Further studies are needed to standardize clinical prognostic scales specific for elderly GBM patients.

Applicability of modified Glasgow Prognostic Score in the assessment of elderly patients with cancer: A pilot study

2015 ◽  
Vol 6 (6) ◽  
pp. 479-483 ◽  
Author(s):  
Viviane Lealdini ◽  
Damila Cristina Trufelli ◽  
Fernanda Borges Ferreira da Silva ◽  
Savia Raquel Costa Normando ◽  
Elisa Watanabe Camargo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Elderly Patients ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Patients With Cancer ◽  
Modified Glasgow Prognostic Score

Dabigatran use in elderly patients with atrial fibrillation

2016 ◽  
Vol 115 (01) ◽  
pp. 152-160 ◽  
Author(s):  
Meytal Avgil-Tsadok ◽  
Cynthia Jackevicius ◽  
Vidal Essebag ◽  
Mark J. Eisenberg ◽  
Elham Rahme ◽  
...  
Keyword(s):  
Propensity Score ◽  
Elderly Patients ◽  
Gastrointestinal Bleeding ◽  
Life Experience ◽  
Real Life ◽  
The Elderly ◽  
Population Based ◽  
Administrative Databases ◽  
Bleeding Events ◽  
Multivariable Analyses

SummaryIn elderly patients (≥75 years), evidence of dabigatran efficacy is lacking and increased vigilance is warranted. We aimed to assess dabigatran effectiveness and safety in elderly patients in real-world practice. We conducted a population-based study using administrative databases, in Quebec (1999–2013). Dabigatran users (110/150 mg) were compared with matched warfarin users with regard to stroke and bleeding events. Age was categorised into < 75 or ≥ 75 years. Propensity score adjusted models were used. The cohort consisted of 15,918 dabigatran users and 47,192 matched warfarin users, with 67.3 % being elderly patients. The elderly predominantly used the lower dose (80.1 %) while younger patients mainly used the higher dose (80.0 %). In multivariable analyses adjusted for propensity score, the risk of stroke in elderly patients using dabigatran, was no different than the risk in warfarin users (HR 1.05, 95 % CI: 0.93, 1.19) regardless of dabigatran dose. However, dabigatran was associated with lower rates of intracranial haemorrhage (HR 0.60, 95 % CI: 0.47–0.76) and higher rates of gastrointestinal bleeding (HR 1.30 95 % CI: 1.14–1.50) when compared to warfarin. Based on real-life experience, dabigatran can offer an alternative to warfarin in elderly patients, with fewer intracranial bleeding events. However, caution is warranted for gastrointestinal bleeding.

scholarly journals Validation of a prognostic score for mortality in elderly patients admitted to Intensive Care Unit

2016 ◽  
Vol 20 (12) ◽  
pp. 695-700 ◽  
Author(s):  
Luis Sanchez-Hurtado ◽  
Adrian Ángeles-Veléz ◽  
Brigette Tejeda-Huezo ◽  
Juan García-Cruz ◽  
Teresa Juárez-Cedillo
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Elderly Patients ◽  
Prognostic Score

scholarly journals Predicting 6-Month Mortality in Incident Elderly Dialysis Patients: A Simple Prognostic Score

2019 ◽  
Vol 45 (1) ◽  
pp. 38-50
Author(s):  
Josefina Santos ◽  
Pedro Oliveira ◽  
Jorge Malheiro ◽  
Andreia Campos ◽  
Sofia Correia ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Prognostic Score ◽  
Treatment Options ◽  
Laboratory Data ◽  
Model Performance ◽  
Area Under The Curve ◽  
Predictive Score ◽  
Multivariable Logistic Regression Analysis ◽  
Patient Centered ◽  
Internal Validation

Aim: Mortality in end-stage renal disease (ESRD) remains high, particularly among elderly, who represents the most rapidly growing segment of the ESRD population in wealthier countries. We developed and validated a risk score in elderly patients to predict 6-month mortality after dialysis initiation. Methods: We used data from a cohort of 421 patients, aged 65 years and over who started dialysis between 2009 and 2016, in our Nephrology department. The predictive score was developed using a multivariable logistic regression analysis. A bootstrapping technique was used for internal validation. Results: The overall mortality within 6 months was 14.0%. Five independent predictors were identified, and a points system was constructed: age 75 years or older (2 points), coronary artery disease (2), cerebrovascular disease with hemiplegia (2), time of nephrology care before dialysis (<3.0 months [2]; ≥3 to <12 months [1]), and serum albumin levels (3.0–3.49 g/dL [1]; <3.0 g/dL [2]). A score of 6 identified patients with a 70% risk of 6-month mortality. Model performance was good in both discrimination (area under the curve of 0.793; [95% CI 0.73–0.86]) and validation (concordance statistics of 0.791 [95% CI 0.73–0.85]). Conclusions: We developed a simple prediction score based on readily available clinical and laboratory data that can be a practical and useful tool to assess short-term prognosis in elderly patients starting dialysis. It may help to inform patients and their families about ESRD treatment options and provide a more patient-centered overall approach to care.

Sign in / Sign up

Export Citation Format

Share Document